News
ZOM
0.1440
+2.93%
0.0041
Weekly Report: what happened at ZOM last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ZOM last week (0311-0315)?
Weekly Report · 03/18 09:48
Zomedica Strives to Maintain NYSE Listing
Zomedica Corp. Is engaged with NYSE American to address compliance issues after failing to meet listing standards. The company's stock will remain listed despite shareholders rejecting a proposed 80:1 reverse stock split. Zomedica specializes in veterinary health products for animals and is listed on the NYSE.
TipRanks · 03/15 13:37
Zomedica says talks ongoing with NYSE American to regain listing compliance
Zomedica says talks ongoing with NYSE American to regain listing compliance. The company says its shares will remain listed on the NYSEAmerican at this time. Zomedica Corp. Says talks are ongoing with New York Stock Exchange to regain compliance with its listing standards.
Seeking Alpha · 03/13 21:12
Zomedica Says Continuing Dialogue With Senior Regulatory Staff At NYSE American Regarding Next Steps To Regaining Compliance With Its Listing Standards
Zomedica shares will remain listed on the NYSE American at this time. A Special Meeting of Shareholders was held on February 28, 2024. The company was unable to effect an 80:1 share consolidation corporate action. Zomedica received formal notice that it was not in compliance with continued listing standards.
Benzinga · 03/13 20:57
Weekly Report: what happened at ZOM last week (0304-0308)?
Weekly Report · 03/11 09:46
Weekly Report: what happened at ZOM last week (0226-0301)?
Weekly Report · 03/04 09:48
Weekly Report: what happened at ZOM last week (0219-0223)?
Weekly Report · 02/26 09:52
Weekly Report: what happened at ZOM last week (0212-0216)?
Weekly Report · 02/19 09:53
Weekly Report: what happened at ZOM last week (0205-0209)?
Weekly Report · 02/12 09:48
Weekly Report: what happened at ZOM last week (0129-0202)?
Weekly Report · 02/05 09:52
Weekly Report: what happened at ZOM last week (0122-0126)?
Weekly Report · 01/29 09:48
Weekly Report: what happened at ZOM last week (0115-0119)?
Weekly Report · 01/22 09:50
Zomedica says Q4 revenue is expected to be over $7M
Healthcare Zomedica says Q4 revenue is expected to be over $7M. Revenue for 2023 is expected in the range of $25M to $35M. The company expects a record quarter in the Therapeutic Device segment. ZomedICA Corp. (ZOM) stock is down 2% in the last week.
Seeking Alpha · 01/17 21:25
Zomedica Announces 1-For-80 Reverse Stock Split
Zomedica will hold a Special Virtual-Only Meeting of Shareholders on February 28, 2024, to seek approval for an 80-1 reverse stock split. The company believes the reverse split will help with a number of initiatives. The reverse split could increase the share price and make Zomedica more attractive to investors.
Benzinga · 01/17 21:03
Weekly Report: what happened at ZOM last week (0108-0112)?
Weekly Report · 01/15 09:48
Weekly Report: what happened at ZOM last week (0101-0105)?
Weekly Report · 01/08 09:50
Weekly Report: what happened at ZOM last week (1225-1229)?
Weekly Report · 01/01 09:47
Weekly Report: what happened at ZOM last week (1218-1222)?
Weekly Report · 12/25/2023 09:52
Zomedica Expands Market Opportunity for Truforma Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
The TRUFORMA cPL cartridge is available for shipping now from Zomedica. The combination Cobalamin & Folate cartridge will be available on December 23, 2023. Canine Pancreatic Lipase, B12 and Folate are the assays used in the testing.
Benzinga · 12/18/2023 11:35
More
Webull provides a variety of real-time ZOM stock news. You can receive the latest news about Zomedica Corp through multiple platforms. This information may help you make smarter investment decisions.
About ZOM
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).